WuXi Advanced Therapies, a global contract development and manufacturing organization (CDMO) offering end-to-end contract services for the advanced therapies industry, has expanded its service capabilities to offer a fully integrated Closed Process CAR-T Cell Therapy Platform. This new platform will accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.

 
"We are excited to launch this world-class Closed Process CAR-T Cell Therapy Platform, which will enhance the integrated support we provide for our customers," said Felix Hsu, senior vice president and global head, WuXi AppTec Advanced Therapies. "We are hopeful that this new platform will not only enable groundbreaking advances in the field of cell and gene therapies, but also allow our customers to deliver innovative treatments to patients with even greater predictability and speed, saving lives in the process."
 
This platform will provide advanced therapy companies worldwide with integrated capabilities for CAR-T production, including: in-stock raw materials with established batch records; regulatory and technical expertise; process and analytical development; full in-process and release testing; robust quality control and quality assurance oversight; and access to facilities that offer the capacity and flexibility to meet companies' timeline needs. The platform also provides one of two modalities depending on dose requirements, using a list of pre-evaluated equipment, technologies and materials with developed closed processes for different unit operations—an innovation that will increase the speed in getting new cell and gene therapies to market.